^
Association details:
Biomarker:No biomarker
Cancer:Myelodysplastic Syndrome
Drug:Promacta (eltrombopag) (Thrombopoietin receptor agonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
11/19/2021
Excerpt:
Myelodysplastic Syndromes: Patients generally ≤60 y and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones. IST includes equine ATG ± cyclosporin A ± eltrombopag.